Literature DB >> 24634239

Gene expression profiling of Duchenne muscular dystrophy reveals characteristics along disease progression.

L J Tian1, J H Cao2, X Q Deng2, C L Zhang2, T Qian2, X X Song2, B S Huang2.   

Abstract

Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy with no cure currently available. In this study, using two microarray data sets obtained from the Gene Expression Omnibus database, we conducted a dysfunctional pathway-enrichment analysis and investigated deregulated genes that are specific to different phases of the disease in order to determine pathogenic characteristics in the progression of DMD. We identified 41 and 33 dysfunctional pathways that were enriched with differentially expressed genes in presymptomatic patients and in symptomatic patients, respectively. Over 70% of pathways were shared between both phases and many of them involved the inflammatory process, suggesting that inflammatory cascades were induced soon after the birth of the patients. Further investigation showed that presymptomatic patients performed better with respect to muscle regeneration and cardiac muscle calcium homeostasis maintenance. Neuronal nitric oxide synthase, dihydropyridine receptors, sarcoplasmic/endoplasmic reticulum calcium ATPase, and phospholamban may serve as potential targets for further molecular diagnostic tests. Our results may provide a better understanding for the treatment of DMD.

Entities:  

Mesh:

Year:  2014        PMID: 24634239     DOI: 10.4238/2014.February.28.13

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  4 in total

1.  Changes in calsequestrin, TNF-α, TGF-β and MyoD levels during the progression of skeletal muscle dystrophy in mdx mice: a comparative analysis of the quadriceps, diaphragm and intrinsic laryngeal muscles.

Authors:  Juliana Barros Maranhão; Drielen de Oliveira Moreira; Adriana Fogagnolo Maurício; Samara Camaçari de Carvalho; Renato Ferretti; Juliano Alves Pereira; Humberto Santo Neto; Maria Julia Marques
Journal:  Int J Exp Pathol       Date:  2015-10-30       Impact factor: 1.925

2.  Skeletal Ryanodine Receptors Are Involved in Impaired Myogenic Differentiation in Duchenne Muscular Dystrophy Patients.

Authors:  Pierre Meyer; Cécile Notarnicola; Albano C Meli; Stefan Matecki; Gérald Hugon; Jérémy Salvador; Mirna Khalil; Léonard Féasson; Claude Cances; Jérôme Cottalorda; Isabelle Desguerre; Jean-Marie Cuisset; Pascal Sabouraud; Alain Lacampagne; Hugues Chevassus; François Rivier; Gilles Carnac
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

3.  Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy.

Authors:  Tirsa L E van Westering; Henrik J Johansson; Britt Hanson; Anna M L Coenen-Stass; Yulia Lomonosova; Jun Tanihata; Norio Motohashi; Toshifumi Yokota; Shin'ichi Takeda; Janne Lehtiö; Matthew J A Wood; Samir El Andaloussi; Yoshitsugu Aoki; Thomas C Roberts
Journal:  Mol Cell Proteomics       Date:  2020-09-29       Impact factor: 5.911

4.  C-X-C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy.

Authors:  Xinsheng Lai; Jie Chen
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.